More News! 10 Aug 2017 Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat patients with idiopathic pulmonary fibrosis (IPF). The median survival is 2 to 5 years after […] August 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 9 Aug 2017 UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2017 Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2017 Demo Day: Meet the Latest Generation of Synbio Startups from RebelBio The RebelBio startups of 2017 reach a major milestone as 15 young companies came forward to explain their ideas, science and how they are selling them. A mere 3 months after the 15 chosen projects for the RebelBio accelerator went off to the labs to refine their prototypes, Demo Day arrived last week on July […] August 4, 2017 - 6 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2017 Designer Babies in Europe: German Merck Set to Receive CRISPR Patent Merck KGaA has received a Notice of Intention to Grant from the European Patent Office that its CRISPR patent will cover genomic integration. Everyone in biotech is gunning for a piece of the CRISPR pie, and German Merck will likely become the next company to acquire IP, adding to the pile it began building in 2012. […] August 3, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2017 Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy TC Biopharm has just received the largest award of its kind to develop allogeneic gamma-delta T cell therapies for various cancers. Based in Glasgow, TC Biopharm was just selected to receive €4M from Horizon 2020 for its “off-the-shelf” gamma-delta T cell program. This grant brings the company’s fundraising total to €25M, and it’s the largest any UK […] August 2, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2017 French Biotech May Save Toddlers from Life-Threatening Peanut Allergy The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies’ Phase IIb results of its peanut allergy therapy, Viaskin Peanut, were one of 2016’s biggest clinical success stories when it successfully desensitized children to obviate life-threatening allergies. A trial in children between the ages […] August 2, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2017 Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems AiCuris’ Pritelivir has now secured FDA endorsement in the form of a Fast Track Designation in immuno-compromised patients. Based in Wuppertal, Germany, and spun out from Bayer, AiCuris is focused on curing infectious diseases. Its lead candidate for herpes simplex viruses 1 and 2 (HSV-1 and -2), pritelivir, has been watched closely for its promise […] August 1, 2017 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2017 Things are Looking Up for UK Synbio Clusters, says Report A survey of synbio startups in the last 16 years shows that the UK ecosystem is growing rapidly and approaching critical mass, says SynbiCITE. Dedicated to championing industrial uptake of synthetic biology, SynbiCITE is a knowledge center based at Imperial College London. Some of its initiatives have included opening a gene foundry last year to providing grants to […] July 28, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2017 Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […] July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2017 AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […] July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2017 German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door for a new generation of better and cheaper vaccines. CureVac, based in Tübingen, Germany, is a pioneer in the development of therapeutic mRNA technology. The company has published today in The Lancet proof-of-concept data from a Phase I trial testing CV7201, […] July 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email